The authors reply

New England Journal of Medicine

Volumn 370, Issue 17, 2014, Pages 1662-1663

  Churchyard, Gavin J ^a   Fielding, Katherine L ^b   Grant, Alison D ^b  

^a AURUM INSTITUTE   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INFECTION CONTROL; LATENT TUBERCULOSIS; LETTER; PRIORITY JOURNAL; TUBERCULOSIS; TUBERCULOSIS CONTROL; MALE; MINING; NOTE;

ANTITUBERCULAR AGENTS; HUMANS; ISONIAZID; MALE; MINING; TUBERCULOSIS;

EID: 84899107333     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1402073     Document Type: Letter

References (4)

1. Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 2006;12:744-51. (Pubitemid 43726847)
2. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010;1:CD000171.
3. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva: World Health Organization, 2011.
4. Samandari T, Agizew TB, Nyirenda S, et al. 6-Month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, doubleblind, placebo-controlled trial. Lancet 2011;377:1588-98.